A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus
antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell
Lung Cancer Patients